Clinical review report: Dapagliflozin (Forxiga)

The objective of this review was to perform a systematic review of the beneficial and harmful effects of dapagliflozin for the treatment of adults with type 2 diabetes who have experienced inadequate glycemic control on combination therapy with metformin and a sulfonylurea

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, April 2016
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01451nam a2200313 u 4500
001 EB001872148
003 EBX01000000000000001035519
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190824 r ||| eng
245 0 0 |a Clinical review report: Dapagliflozin (Forxiga)  |h Elektronische Ressource 
246 3 1 |a CDR clinical review report for Forxiga MET + SFU 
246 3 1 |a Dapagliflozin (Forxiga) 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2016, April 2016 
300 |a 1 PDF file (ix, 62 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Glucosides / therapeutic use 
653 |a Canada 
653 |a Benzhydryl Compounds / therapeutic use 
653 |a Diabetes Mellitus, Type 2 / drug therapy 
653 |a Sodium-Glucose Transporter 2 Inhibitors 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 |u https://www.ncbi.nlm.nih.gov/books/NBK538725  |3 Volltext 
082 0 |a 610 
520 |a The objective of this review was to perform a systematic review of the beneficial and harmful effects of dapagliflozin for the treatment of adults with type 2 diabetes who have experienced inadequate glycemic control on combination therapy with metformin and a sulfonylurea